Italia Markets closed

Astria Therapeutics, Inc. (ATXS)

NasdaqGM - NasdaqGM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
10,81-0,45 (-4,00%)
Alla chiusura: 04:00PM EDT
10,52 -0,29 (-2,68%)
Dopo ore: 07:12PM EDT

Astria Therapeutics, Inc.

75 State Street
Suite 1400
Boston, MA 02109
United States
617 349 1971
https://www.astriatx.com

Settore/iHealthcare
SettoreBiotechnology
Impiegati a tempo pieno59

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Ms. Jill C. Milne Ph.D.Co-Founder, CEO, President & Director928,52kN/D1968
Mr. Benjamin S. Harshbarger J.D.Chief Legal Officer621,91kN/D1969
Mr. Noah C. Clauser CPACFO & Treasurer508,79kN/D1974
Ms. Keri McGrailSenior Vice President of Human ResourcesN/DN/DN/D
Ms. Andrea L. MatthewsChief Business OfficerN/DN/DN/D
Mr. Andrew A. KomjathyChief Commercial OfficerN/DN/D1964
Dr. Christopher J. Morabito M.D.Chief Medical OfficerN/DN/D1971
Mr. John RueschSenior Vice President of Pharmaceutical Sciences & Technical OperationsN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Astria Therapeutics, Inc. al 1 aprile 2024 è 7. I criteri di valutazione fondamentali sono revisione: 5; Consiglio di Amministrazione: 7; diritti degli azionisti: 8; retribuzione: 7.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.